Global BD&L and M&A Contacts

Early stage: Research up to Proof-of Concept (Phase 2a)
Late stage: Post Proof of Concept (beyond Phase 2a)

<table>
<thead>
<tr>
<th>Therapeutic Areas</th>
<th>Early stage:</th>
<th>Late stage:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardio-Metabolic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early stage:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avi Spier</td>
<td>Head, Search &amp; Evaluation</td>
<td>Mireia Gomez</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:avi.spier@novartis.com">avi.spier@novartis.com</a></td>
<td>Global Head, Search &amp; Evaluation Cardio-Metabolic</td>
</tr>
<tr>
<td></td>
<td></td>
<td><a href="mailto:pharmabdl.cm_se@novartis.com">pharmabdl.cm_se@novartis.com</a></td>
</tr>
<tr>
<td>Late stage:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early stage:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avirup Bose</td>
<td>Head, Search &amp; Evaluation</td>
<td>Markus Kalousek</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:avirup.bose@novartis.com">avirup.bose@novartis.com</a></td>
<td>Global Head, Search &amp; Evaluation Pharma</td>
</tr>
<tr>
<td></td>
<td></td>
<td><a href="mailto:pharmabdl.ihd_se@novartis.com">pharmabdl.ihd_se@novartis.com</a></td>
</tr>
<tr>
<td>Late stage:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunology &amp; Dermatology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early stage:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Axel Maibuecher</td>
<td>Head, Search &amp; Evaluation</td>
<td>Markus Kalousek</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:axel.maibuecher@novartis.com">axel.maibuecher@novartis.com</a></td>
<td>Global Head, Search &amp; Evaluation Pharma</td>
</tr>
<tr>
<td></td>
<td></td>
<td><a href="mailto:pharmabdl.ihd_se@novartis.com">pharmabdl.ihd_se@novartis.com</a></td>
</tr>
<tr>
<td>Late stage:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal Diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early stage:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dominic Ehrismann</td>
<td>Head, Search &amp; Evaluation</td>
<td>Patrick Mueller</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:dominic.ehrismann@novartis.com">dominic.ehrismann@novartis.com</a></td>
<td>Global Head, Search &amp; Evaluation Neuroscience</td>
</tr>
<tr>
<td></td>
<td></td>
<td><a href="mailto:pharmabdl.msd_se@novartis.com">pharmabdl.msd_se@novartis.com</a></td>
</tr>
<tr>
<td>Late stage:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuroscience</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early stage:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chi-Chi Zhu</td>
<td>Head, Search &amp; Evaluation</td>
<td>Patrick Mueller</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:chi-chi.zhu@novartis.com">chi-chi.zhu@novartis.com</a></td>
<td>Global Head, Search &amp; Evaluation Neuroscience</td>
</tr>
<tr>
<td></td>
<td></td>
<td><a href="mailto:pharmabdl.ns_se@novartis.com">pharmabdl.ns_se@novartis.com</a></td>
</tr>
<tr>
<td>Late stage:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ophthalmology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early stage:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adam Feire</td>
<td>Head, Search &amp; Evaluation</td>
<td>Dimitrios Lizos</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:adam.feire@novartis.com">adam.feire@novartis.com</a></td>
<td>Global Head, Search &amp; Evaluation Ophthalmology</td>
</tr>
<tr>
<td></td>
<td></td>
<td><a href="mailto:pharmabdl.ophtha_se@novartis.com">pharmabdl.ophtha_se@novartis.com</a></td>
</tr>
<tr>
<td>Late stage:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Early-stage includes all activities from research up to Proof-of-Concept (defined as Ph2a).
### Renal / Nephrology

**Early stage:**
- **Cindy Hong**  
  Associate Director, Search & Evaluation  
  cynthia.hong@novartis.com

**Late stage:**
- **Mireia Gomez**  
  Global Head, Search & Evaluation Cardio-Metabolic  
  pharmabdl.cm_se@novartis.com

### Respiratory

**Early stage:**
- **Dominic Ehrismann**  
  Head, Search & Evaluation  
  dominic.ehrismann@novartis.com

**Late stage:**
- **Ken Shaw**  
  Global Head, Search & Evaluation Respiratory  
  pharmabdl.resp_se@novartis.com

### Oncology

**Early stage:**
- **Reza Mazhari**  
  Head, Search & Evaluation  
  reza.mazhari@novartis.com

**Late stage:**
- **Sree Anumolu**  
  Director, Oncology BD&L  
  sree.anumolu@novartis.com

### Immuno-Oncology

**Early stage:**
- **Michael Woo**  
  Head, Search & Evaluation  
  michael.woo@novartis.com

**Late stage:**
- **Sree Anumolu**  
  Director, Oncology BD&L  
  sree.anumolu@novartis.com

### Benign hematology

**Early stage:**
- **Avirup Bose**  
  Head, Search & Evaluation  
  avirup.bose@novartis.com

**Late stage:**
- **Sree Anumolu**  
  Director, Oncology BD&L  
  sree.anumolu@novartis.com

### White spaces

**Early stage:**
- **Avirup Bose**  
  Head, Search & Evaluation  
  avirup.bose@novartis.com

**Late stage:**
- **Troy Dale**  
  New Products Head SPT, BD&L  
  pharmabdl.spt_se@novartis.com

### Platforms and Technologies

### Cell & Gene Therapy

**Early stage:**
- **Phil Gotwals**  
  Global Head, Search & Evaluation  
  phil.gotwals@novartis.com

**Late stage:**
- **Sree Anumolu**  
  Director, Oncology BD&L  
  sree.anumolu@novartis.com
  
  **Troy Dale**  
  New Products Head SPT, BD&L  
  pharmabdl.spt_se@novartis.com

---

Note: Early-stage includes all activities from research up to Proof-of-Concept (defined as Ph2a).
### Digital

**Early stage:**

**Cindy Hong**  
Associate Director, Search & Evaluation  
cynthia.hong@novartis.com

**Late stage:**

**Jeremy Sohn**  
Global Head Digital Development and BD&L  
jeremy.sohn@novartis.com

---

### Precision Medicine – Diagnostic Technologies

**Guy Greiveldinger**  
Head of Precision Medicine BD&L, Oncology  
guy.greiveldinger@novartis.com

---

### Biologics

**Adam Feire**  
Head, Search & Evaluation  
adam.feire@novartis.com

### Chemistry & Chemical Biology

**Avi Spier**  
Head, Search & Evaluation  
avi.spier@novartis.com

---

### Sandoz

#### Small Molecules & Generics

**Ben Toogood**  
Global Head, Business Development & Licensing Sandoz Small Molecules  
business.development@sandoz.com

#### Biopharmaceuticals

**Ulrich Osswald**  
Global Head, Business Development & Licensing Sandoz Biopharmaceuticals  
biopharmbusiness.development@sandoz.com

---

### Other Divisions & Functions

#### M&A

**Keren Haruvi**  
Global Head, M&A  
keren.haruvi@novartis.com

#### Alliance Management

**Knut Sturmhoefel**  
Global Head, Alliance Management  
knut.sturmhoefel@novartis.com

#### Venture Investments

**Marc Ceulemans**  
Head Capital Venture Fund Management, BD&L  
marc.ceulemans@novartis.com

#### Out-licensing and Divestments

**Jean-Marc Sequier**  
Global Head, Divestment & Out-Licensing  
jeanmarc.sequier@novartis.com

**Reza Mazhari**  
Head, Search & Evaluation  
reza.mazhari@novartis.com

---

*Note: Early-stage includes all activities from research up to Proof-of-Concept (defined as Ph2a).*